Tvardi Therapeutics (TVRD) Price & Analysis

Compare

2,528 Followers

TVRD Stock Chart & Stats

$4.23

Market closed

$4.23

Day’s Range― - ―

52-Week Range$3.74 - $43.65

Previous CloseN/A

VolumeN/A

Average Volume (3M)401.55K

Market Cap

$36.49M

Enterprise Value$156.52M

Total Cash (Recent Filing)$40.99M

Total Debt (Recent Filing)$254.00K

Price to Earnings (P/E)―

Beta0.25

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding9,381,344

10 Day Avg. Volume1,070,842

30 Day Avg. Volume401,545

Financial Highlights & Ratios

PEG Ratio>-0.01

Price to Book (P/B)-1.62

Price to Sales (P/S)1.04

P/FCF Ratio-0.12

Enterprise Value/Market Cap4.29

Enterprise Value/Revenue23.79

Enterprise Value/Gross Profit24.39

Enterprise Value/Ebitda-5.85

Forecast

1Y Price Target

$9.20

Price Target Upside117.49% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering7

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Addressable Market ExpansionManagement's plan to evaluate TTI-109 in additional STAT3-driven and anti-fibrotic indications could expand the drug's market potential across oncology and fibrotic diseases.

Clinical Development ProgressionAdvancement into healthy‑volunteer studies and anticipated Phase 1b/2 progression for the next‑generation STAT3 inhibitor could validate translational promise and accelerate patient‑level testing.

Improved Oral BioavailabilityTTI-109's prodrug design achieves substantially higher oral bioavailability, which could enable simpler dosing and improve drug exposure in target tissues, supporting broader clinical use.

Bears Say

Analyst Valuation PressureMultiple price‑target reductions and higher discount rates applied by analysts reflect diminished confidence in revenue prospects and could exert further downward pressure on the stock.

Phase 2 Efficacy SetbackPreliminary REVERT-IPF results showing no discernible benefit on lung function undermine core efficacy expectations for the IPF program and weaken commercial outlook.

Tolerability And Discontinuation ConcernsHigher discontinuation rates linked to gastrointestinal adverse events raise tolerability doubts that could limit patient retention and complicate regulatory or commercial paths.

Tvardi Therapeutics News

Tvardi Therapeutics announces further Phase 2 REVERT IPF data

Tvardi Therapeutics (TVRD) provided further updates from its Phase 2 REVERT IPF clinical trial of TTI-101 in idiopathic...

2d ago

TVRD

Tvardi Therapeutics: Buy Rating Reaffirmed Amid Upcoming Catalysts and Risk-Reward Scenario

JonesTrading analyst Debanjana Chatterjee has maintained their bullish stance on TVRD stock, giving a Buy rating on November...

2M ago

TVRD

Tvardi Therapeutics Advances STAT3 Inhibitor Clinical Trials

An announcement from Tvardi Therapeutics ( ($TVRD) ) is now available. Tvardi Therapeutics announced significant progress in its...

2M ago

TVRD

Tvardi Therapeutics Faces Financial Hurdles Amidst Ongoing Product Development Challenges

Tvardi Therapeutics Inc. (TVRD) has disclosed a new risk, in the Accounting & Financial Operations category. Tvardi Therapeutics...

2M ago

TVRD

Promising Pipeline and Financial Stability Drive Buy Rating for Tvardi Therapeutics

BTIG analyst Julian Harrison maintained a Buy rating on Tvardi Therapeutics yesterday and set a price target of...

2M ago

TVRD

Tvardi Therapeutics reports Q3 EPS (59c), consensus (96c)

Cash, cash equivalents and short-term investments as of September 30, 2025, were $36.5 million, as compared to $31.6...

2M ago

TVRD

Tvardi Therapeutics’ Liver Cancer Study: A Potential Game-Changer?

Tvardi Therapeutics Inc. (($TVRD)) announced an update on their ongoing clinical study. Tvardi Therapeutics Inc. is conducting a...

2M ago

TVRD

Tvardi downgraded to Market Perform from Outperform at Raymond James

Raymond James downgraded Tvardi Therapeutics (TVRD) to Market Perform from Outperform without a price target The firm believes...

3M ago

TVRD

Tvardi Therapeutics Faces Setback in Phase 2 Trial

The latest update is out from Tvardi Therapeutics ( ($TVRD) ). On October 13, 2025, Tvardi Therapeutics provided...

3M ago

TVRD

Optimistic Buy Rating for Tvardi Therapeutics: Promising Potential of TTI-109 Amidst TTI-101 Setbacks

Julian Harrison, an analyst from BTIG, maintained the Buy rating on Tvardi Therapeutics. The associated price target is...

3M ago

TVRD

Tvardi Therapeutics downgraded to Equal Weight from Overweight at Barclays

Barclays downgraded Tvardi Therapeutics (TVRD) to Equal Weight from Overweight with a price target of $5, down from...

3M ago

TVRD

Morning News Wrap-Up: Monday’s Biggest Stock Market Stories!

Traders looking for the top stock market stories on Monday will find them in TipRanks’ daily wrap-up. ...

3M ago

AMD

Cantor downgrades Tvardi Therapeutics, sees ‘no path forward in IPF’

As previously reported, Cantor Fitzgerald downgraded Tvardi Therapeutics (TVRD) to Neutral from Overweight after the company provided an...

3M ago

TVRD

Tvardi Therapeutics downgraded to Neutral from Overweight at Cantor Fitzgerald

Cantor Fitzgerald downgraded Tvardi Therapeutics (TVRD) to Neutral from Overweight. Published first on TheFly – the ultimate source...

3M ago

TVRD

TVRD FAQ

What was Tvardi Therapeutics’s price range in the past 12 months?

Tvardi Therapeutics lowest stock price was $3.74 and its highest was $43.65 in the past 12 months.

What is Tvardi Therapeutics’s market cap?

Tvardi Therapeutics’s market cap is $36.49M.

When is Tvardi Therapeutics’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Tvardi Therapeutics’s earnings last quarter?

Currently, no data Available

Is Tvardi Therapeutics overvalued?

According to Wall Street analysts Tvardi Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Tvardi Therapeutics pay dividends?

Tvardi Therapeutics does not currently pay dividends.

What is Tvardi Therapeutics’s EPS estimate?

Tvardi Therapeutics’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Tvardi Therapeutics have?

Tvardi Therapeutics has 9,381,344 shares outstanding.

What happened to Tvardi Therapeutics’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Tvardi Therapeutics?

Currently, no hedge funds are holding shares in TVRD

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Tvardi Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-97.61%

Trailing 12-Months

Asset Growth

-39.65%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Tvardi Therapeutics

Tvardi Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need. Their lead candidate, TTI-101, is currently in Phase 2 clinical trials for idiopathic pulmonary fibrosis (IPF) and hepatocellular carcinoma (HCC).

Tvardi Therapeutics (TVRD) Earnings & Revenues

Historic Earnings Reports

TVRD Stock 12 Month Forecast

Average Price Target

$9.20

▲(117.49% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","11":"$11","20":"$20","29":"$29","38":"$38"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":15,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$15.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9.2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$9.20</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$4.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,11,20,29,38],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.91,4.763076923076923,5.616153846153846,6.469230769230769,7.322307692307692,8.175384615384615,9.028461538461539,9.881538461538462,10.734615384615385,11.587692307692308,12.44076923076923,13.293846153846154,14.146923076923077,{"y":15,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.91,4.316923076923077,4.723846153846154,5.13076923076923,5.537692307692307,5.944615384615384,6.351538461538461,6.758461538461538,7.165384615384615,7.5723076923076915,7.979230769230768,8.386153846153846,8.793076923076923,{"y":9.2,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.91,3.916923076923077,3.9238461538461538,3.930769230769231,3.937692307692308,3.9446153846153846,3.9515384615384614,3.9584615384615387,3.9653846153846155,3.9723076923076923,3.979230769230769,3.9861538461538464,3.993076923076923,{"y":4,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":10.69,"date":1730419200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":10.47,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":18.36,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":14.34,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":14.82,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.45,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.76,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.15,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.2,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.58,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.82,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.65,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.91,"date":1764547200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >